Professor Paul Workman - Improving the outcome for Cancer Patients

Synopsis

• One in two of the UK population will suffer from cancer in their lifetime, with a cancer prognosis made every two minutes in the UK
• Survival rates are improving but still only 50% of cancer patients survive more than 10 years from diagnosis
• A combination of innovative targeted therapies are being developed while improving detection methods could greatly improve survival rates

Overall cancer survival rates are rising, but among the 200 known cancers these rates remain relatively poor. The major challenges we face when improving survival rates are the varying cell populations per patient and the emergence of resistance. Using our knowledge of genetics and the biology of cancer, scientists have discovered new drugs that are targeted to specific genetic subtypes. This has evolved into important breakthroughs in stimulating the immune response.

During his Public Evening Lecture, on Wednesday 27 February 2019, Professor Paul Workman will discuss how outcomes will be improved for cancer patients in the future, including developments in early detection, accurate diagnosis and prevention, new therapies for control and cure, and the impact of AI.

Programme

About the Speaker

Professor Paul Workman is the Chief Executive and President of the Institute of Cancer Research (ICR) in London, where he is also a Harrap Professor of Pharmacology and Therapeutics. From 1997 to 2016, he was Director of the Cancer Research UK Cancer Therapeutics Unit at the ICR - the world’s largest non-profit cancer drug discovery group. Before joining the ICR, Professor Workman spent four years leading cancer research at AstraZeneca and prior to that worked at Glasgow, Stanford, and Cambridge Universities. He was a scientific founder of Piramed Pharma, which was acquired by Roche, and Chroma Therapeutics.

He has been responsible for more than 20 molecularly targeted cancer drugs entering clinical trial, and Professor Workman is especially renowned for his innovative research in the discovery, chemical biology, and molecular pharmacology of drugs and chemical probes acting on highly innovative molecular targets. In 2016, he became a Fellow of the Royal Society.

Venue and Contact

Fees

Booking Process

Booking terms and conditions

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Additional Info

Exhibition and Sponsorship

An exhibition will take place alongside the conference for companies and related organisations who may wish to exhibit. Please email conferences@soci.org for further information and prices. Spaces are limited and will be allocated on a first-come, first-served basis.